(Reuters)—Pharmaceutical companies have ramped up clinical trials in the past month, rebounding from a steep decline in activity following the start of the COVID-19 outbreak, though activity remains below pre-pandemic levels, according to new research shareS with Reuters. The research, which was prepared by clinical trial consulting firm Medidata, shows that new subjects entered trials…
With Apps & Remote Medicine, Japan Offers Glimpse of Doctor Visits in Post-COVID-19 Era
TOKYO (Reuters)—The coronavirus crisis has prompted Japan to ease regulations on remote medical treatment, creating an opening for tech companies and offering a glimpse of the future of healthcare in the world’s most rapidly aging society. As coronavirus cases spiked in April, Japan temporarily eased restrictions on remote medical care, allowing doctors to conduct first-time…
ACR Releases Clinical Guidance for Patients with Multisystem Inflammatory Syndrome in Children
The recommendations for MIS-C focus on general guidance, diagnostic evaluation and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki disease.
ACR Releases COVID-19 Clinical Guidance for Pediatric Patients with Rheumatic Disease
The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.
Caring for Pediatric Patients During a Pandemic: Q&A with Jay Mehta, MD
Caring for pediatric patients during a pandemicin the age of COVID-19 requires adaptations, says Jay Mehta, MD, Children’s Hospital of Philadelphia. “The one exposure that seems to put [pediatric] patients at risk is if they are on higher doses of steroids, with some data suggesting worse outcomes. We just put out guidelines telling providers to reduce steroids in their patients to the lowest dose that can adequately control their disease.”
Joint Letter to CMS Advocates Against Adding Stelara to Self-Administered Drug List
The ACR, CSRO and Arthritis Foundation asked the Centers for Medicare & Medicaid Services to review the decision to add Stelara to the Self-Administered Drugs list, which would limit access for patients who can’t self-administer.
The ACR Releases New Telemedicine Position Statement
The rapid expansion of telemedicine in rheumatology, as well as changes to reimbursement and relaxed regulations, during the COVID-19 pandemic has served as an impetus for the ACR to review its position and release a new statement in support of optimized telemedicine practices.
Biosimilar Prescribing Habits in the VA & Academic Settings
In a new study, Baker et al. examined reference product and biosimilar orders, comparing data from a Veterans Affairs Medical Center (VAMC) to those from an academic medical center…
Unified Signature of SLE May Advance Clinical Diagnosis & Biomarker Development
Researchers have identified 93 genes that may play a role in systemic lupus erythematosus (SLE), including 47 genes not previously associated with SLE. Theresulting transcriptome has revealed underappreciated genes and pathways associated with the pathogenesis of SLE…
Zoledronate After Denosumab Does Not Fully Prevent Bone Loss
NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…
- « Previous Page
- 1
- …
- 75
- 76
- 77
- 78
- 79
- …
- 309
- Next Page »